Connect with us

Hi, what are you looking for?

Latest News

Syrian first lady Asma al-Assad diagnosed with leukemia, president’s office says

The first lady of Syria, Asma al-Assad, has been diagnosed with leukemia, according to the nation’s top officials.

Asma al-Assad, wife of Syrian President Bashar al-Assad, has been forced to temporarily withdraw from public life for the time being due to the disease.

She was diagnosed with acute myeloid leukemia and will ‘adhere to a specialized treatment protocol that includes stringent infection prevention measures,’ according to a statement released by her husband’s office on Tuesday.

Following the outbreak of the Syrian civil war in 2011, Ama al-Assad became involved in charity work for national interests championed by her husband, who has been accused in France of alleged complicity in war crimes.

She makes frequent public appearances and hosts meetings with the families of fallen soldiers.

She also accompanied her husband during a diplomatic visit to the United Arab Emirates in 2023. It was her first trip out of the country since the civil war began.

Asma al-Assad is a British citizen born in London to parents of Syrian descent.

She has been diagnosed with life-threatening illnesses in the past, including breast cancer. She was deemed cancer-free in 2019.

She met her husband, Bashar al-Assad, through family connections. The couple has been married since 2000, when Bashar took office for the presidency.

Prior to their relationship, Asma was employed as an investment banker at J.P. Morgan.

This post appeared first on FOX NEWS

You May Also Like

Latest News

Independent presidential candidate Robert F. Kennedy, Jr. has revealed what he says is his path to the White House as he faces increased pressure...


In this edition of StockCharts TV‘s The Final Bar, Dave uncovers strength in SQSP using the Stochastics Oscillator and the StochRSI indicator. He shares...


Over the past trading week, it was expected that while technical pullbacks in the markets may get extended, NIFTY may still continue to remain...


We’ve been covering the signs of weakness for stocks, from the bearish divergences in March, to the mega-cap growth stocks breaking through their 50-day...

Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023